Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03064438 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea
A Phase 2 study of Acne Rosacea, sponsored by Accuitis.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT03064438 is a Phase 2 study of Acne Rosacea that has completed, run by Accuitis. The registered enrollment target is 40 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03064438, a Phase 2 study of Acne Rosacea, has completed, sponsored by Accuitis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study evaluated the safety, tolerability, and efficacy of ACCU-D1 when applied twice daily for 12 weeks in adult participants with moderate to severe acne rosacea. Two-third of the participants received ACCU-D1 while one-third of the participants received vehicle control.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG ACCU-D1
Study Locations (2)
Kentucky
- DS Research - Louisville
Texas
- DermResearch - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-11-28 |
| Est. Completion | 2018-06-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03064438
The ClinicalTrials.gov registry entry for NCT03064438 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accuitis, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Rosacea appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT03064438 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kentucky, Texas.
Frequently Asked Questions
What is clinical trial NCT03064438 about?
NCT03064438 is a clinical study titled "Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea". The study evaluated the safety, tolerability, and efficacy of ACCU-D1 when applied twice daily for 12 weeks in adult participants with moderate to severe acne rosacea. Two-third of the participants received ACCU-D1 while one-third of the participants received vehicle control.
What is the current status of trial NCT03064438?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2017-11-28. Estimated completion is 2018-06-18.
What conditions does trial NCT03064438 study?
This clinical trial studies the following conditions: Acne Rosacea.
What interventions are being tested in trial NCT03064438?
The interventions under investigation include: Vehicle (DRUG), ACCU-D1 (DRUG).
Who is sponsoring clinical trial NCT03064438?
This trial is sponsored by Accuitis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03064438 being conducted?
This trial has 2 study locations across Kentucky, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.